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Abstract FMRFaraide-related peptides have been isolated from 
both invertebrates and vertebrates and exhibit a wide range 
of biological effects in rats. We show here that in humans 
2 FMRFamide-related peptides are encoded by a single gene 
expressed as a spliced mRNA. The larger predicted peptide 
(AGEGLNSQFWSLAAPQRFamide) differs from the peptide 
isolated from bovines (AGEGLSSPFWSLAAPQRFamide) by 
the substitutions of 2 amino acids. The shorter predicted peptide 
(NPSF, SQAFLFQPQRFamide) is 3 amino acids longer than 
the bovine 8 amino-acid NPFF (FLFQPQRFamide) or the 
human NPFF peptide isolated from serum [5], suggesting that the 
encoded protein is subject to cleavage by a tripeptidyl peptidase 
or by a novel processing mechanism. On rat spinal cord, the 
larger peptide is indistinguishable in activity from the equivalent 
bovine peptide whereas the smaller extended peptide is inactive. 
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In bovine brain, 3 different forms of immunoreactive mate-
rial were detected by HPLC separation and the use of an 
antibody raised against the molluscan peptide FMRF-NH2 . 
Two of these correspond to NPFF and NPAF ; the structure 
of the third is unknown [12]. Similarly, in the rat hypothal-
amus, NPFFs have been shown to exist by HPLC and immu-
noreactivity but the predominant form of peptide is not 
NPFF [13]. 
The isolation of the human gene described here now allows 
a definitive description of the human FMRFamide peptides. 
We show that there is an additional 3 amino acids on the 
human NPFF precursor that must be cleaved to produced 
biologically active NPFF. If these amino acids are present 
on the precursor of the bovine and rat NPFF then this could 
account for the alternate form detected by HPLC. We also 
demonstrate that human NPAF is capable of modulating neu-
ral activity in the rat spinal cord in a manner indistinguishable 
from that of bovine NPAF while human N-terminally ex-
tended NPFF has no activity. 
1. Introduction 
FMRFamide-related peptides were originally isolated from 
molluscs [1] and subsequently from many species, including 
Drosophila [2], C. elegans [3] and bovines [4]. 
Neuropeptide FF (NPFF, FLFQPQRF-NH2) and the re-
lated neuropeptide AF (NPAF, AGEGLSSPFWSLAAPQRF-
NH2) were originally isolated from the bovine brain using an 
antibody raised against the molluscan peptide FMRF-NH2 
[4], and more recently NPFF has been detected in human 
serum [5]. These peptides have wide-ranging physiological ef-
fects, in particular the modulation of morphine-induced anal-
gesia [6], elevation of arterial blood pressure [7] and increased 
somatostatin secretion from the pancreas [8]. 
By the use of immunohistochemistry and binding studies it 
has been shown that the rat spinal cord contains an intrinsic 
NPFF system. Cell bodies in the dorsal horn react to anti-
bodies against NPFF and specific high-affinity binding sites 
for NPFF have been demonstrated [9,10]. A specific binding 
site for an iodinated analogue of NPFF, 125I-YLFQPQRF-
amide, has also been found in human spinal cord and medul-
la, the highest density being in the spinal trigeminal nucleus 
[11], suggesting that release of NPFF-related peptides from 
the immunoreactive neurons may bind to this highly specific 
receptor. 
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2. Materials and methods 
2.1. Isolation of cDNA clones encoding human FMRFamide-like 
peptides 
A full-length cDNA clone was isolated from a human testis cDNA 
A.gtl0 library (Clontech) using a random primed a-32P-dCTP-radio-
labelled cDNA probe encoding part of the human FMRFamide pro-
peptide. Hybridization was performed on duplicate filters of 3X104 
plaques (6 plates with 5000 pfu/plate) at 65°C overnight (hybridiza-
tion buffer: 5XSSC, 0.1% w/v SDS, 8% w/v PEGgooo, 5XDenhardt's 
solution, 0.1 M Na2HP04/NaH2P04) followed by stringent washing 
(three 20-min washes at 65°C, with 0.1 XSSC/0.1% SDS) [14]. Filters 
were placed on pre-flashed Kodak Xomat X-ray film overnight. Pos-
itively hybridizing plaques were purified through secondary and ter-
tiary screens and the cDNA clones were isolated by PCR amplifica-
tion from the A.gtl0 forward and reverse primer sites (PCR 
conditions: 50 mM KC1, 10 mM Tris-HCl pH 8.0, 2.5 mM MgCl2, 
200 uM each dNTP, 50 pmol each primer, 2 U Taq polymerase 
(Promega), =109 phage in phage suspension buffer; 25 cycles of 
94°C for 30 s, 55°C for 30 s, 72°C for 1 min). The products were 
cloned into the pTAG vector (R and D Systems, UK) and subjected 
to fluorescence-based cycle sequencing on an ABD 373A automated 
DNA sequencer. 
2.2. PCR amplification of the human FMRFamide gene from 
genomic DNA 
Oligonucleotide primers corresponding to positions within the 
cDNA sequence were used to amplify the equivalent regions from 
human genomic DNA (5'UTR: CATGAAGTCCTGGGGGCGC 
and 3'UTR: CAGAAGCCAGACAATTTTATTTGG; Fl : GCAGG-
CTGCTGCACTGCT-GGT and F2rev: CTCAGCCATTCATTCCT-
CCAGGA; F2: TCACTGTTGCACTACC-TGCTCCA and F2rev). 
PCR reactions were performed in 50-ul vols, using 50 pmol of each 
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primer, 200 ng of genomic DNA (isolated from human fibroblast 
tissue culture cells) or 10 pg of cloned cDNA (cycling conditions: 
3 cycles at 94°C for 2 min and 63°C for 2 min, followed by 27 cycles 
at 94°C for 30 s, 63°C for 30 s, 72°C for 1 min). Products were 
separated by agarose gel electrophoresis and visualized by ethidium 
bromide staining. All PCR products generated from genomic DNA 
were cloned into the pTAG vector (R and D Systems, UK) and sub-
jected to fluorescence-based cycle sequencing. 
2.3. Dissection and preparation of rat spinal cords for 
electrophysiological recording 
The method of dissection and preparation is previously described in 
[15]. Briefly, albino rats weighing 20-30 g were lightly anaesthetized 
with halothane prior to decapitation. A block of tissue containing the 
vertebral column was rapidly excised and chilled by immersion in 
artificial cerebrospinal fluid on ice (ACSF: 118 mM NaCl, 3 mM 
KC1, 24 mM NaHC0 3 , 2.5 mM CaCl2, 12 mM glucose; gassed 
with 95% 02 /5% C 0 2 pH 7.4). Under continuous flow of cold 
ACSF, the cord was exposed from the ventral surface, and the entire 
length of the cord, complete with intercostal nerves to segments T2, 
T6 and T12, and all the lumbar roots were dissected free from the 
vertebral column. The ventral roots were cut and the entire cord was 
mounted in the recording chamber. The dissection usually took 30-60 
min to complete. The recording chamber was continually perfused 
with oxygenated ACSF at 18-20°C. Three or four lumbar dorsal roots 
were mounted on silver wire stimulating electrodes. Desiccation of the 
roots was prevented by covering all exposed tissue with a mixture of 
petroleum jelly and liquid paraffin. 
2.4. Measurement of the effects of human and bovine RFamide peptides 
on an isolated rat spinal cord preparation 
Stimulation with 0.5-ms 5-10-V pulses (5X threshold for each in-
dividual preparation) of lumbar dorsal roots through silver wire stim-
ulating electrodes were made whilst perfusing the entire preparation 
with human or bovine NPAF, human NPSF or bovine NPFF dis-
solved in ACSF. Recordings were made from lumbar ventral roots 
using a suction electrode, and a microcomputer recording system 
based on a multichannel interface unit (Grafitek SP9) and an IBM-
PC compatible computer (Tandon PC A). 
2.5. Measurement of the effect of human NPAF on spontaneous activity 
in lumbar dorsal roots 
Suction electrodes were attached to lumbar dorsal roots in the same 
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Fig. 1. Primary structure of the human FMRFamide-like peptide 
precursor. A cDNA clone of 591 bp encoding an 113-residue open 
reading frame was isolated from a human testis cDNA library. The 
deduced translation of the cDNA clone revealed structures of two 
probable FMRFamide-related peptides (underlined). Both peptides 
are flanked by single or pairs of basic amino acids (bold) which act 
as endopeptidase cleavage sites. The precursor is preceeded by a hy-
drophobic leader sequence (residues 1-16) with a predicted cleavage 
site after Cys-20 (arrow head). Nucleotide and amino-acid (under-
lined) positions are given on the right. 
Fig. 2. The genomic organization of the human FMRFamide-like 
peptide gene, a: PCR products amplified from two primer pairs on 
both human genomic DNA and an isolated cDNA clone were sepa-
rated by agarose gel electrophoresis. Primer set Fl/F2rev amplified 
products of 612 bp from genomic DNA (lane 1) and 258 bp from 
the cDNA sequence (lane 2). Primer set F2/F2rev amplified prod-
ucts of 246 bp from genomic DNA (lane 3) and 120 bp from the 
cDNA sequence (lane 4). Marker (M) 100-bp ladder (Gibco-BRL). 
b : PCR products from Fig. a were purified and subjected to auto-
mated cycle sequencing. Half arrows represent positions of PCR pri-
mers used in Fig. a. The deduced structure of the gene contains 
3 exons of 267 bp (El), 120 bp (E2) and 204 bp (E3) and 2 introns 
of 227 bp (II) and 127 bp (12) within the open reading frame (white 
bars); the 2nd intron interrupts the shorter predicted peptide se-
quence, NPSF (black bars). The longer peptide (diagonal striped 
bar) is encoded entirely by E3. 
preparation as described above. Recordings of spontaneous extracel-
lular action potentials were made in 30 successive 15-s bins using a 
spike discriminator, before and during perfusion with human NPAF 
dissolved in ACSF. 
3. Results 
3.1. The human FMRFamide-related peptide gene 
The site of synthesis of mammalian FMRFamide-re la ted 
peptides is not known. In order to identify FMRFamide- re -
lated transcripts, a human expressed sequence tag (EST) data-
base was searched for sequences homologous to the bovine 
peptides. F r o m a screen of > 300 000 ESTs, 2 potential pos-
itives were identified. Both sequences were found in a c D N A 
library constructed from human epididymus m R N A . Full-
length c D N A s (591 bp) were subsequently isolated by screen-
ing a human testis library (Clontech) using the ESTs as hy-
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taining 2 FMRFamide-like peptides both related to biochemi-
cally isolated bovine peptides [4]. The 6th amino acid (Ser) of 
the longer bovine peptide (NPAF) is replaced by Asn in the 
predicted human sequence, and the 8th amino acid Pro by 
Gin. Proteolytic processing of the neuropeptide probably oc-
curs by cleavage at Arg-92 and Lys-112 with amidation occur-
ring at Gly-111. The smaller bovine peptide, 8th amino-acid 
neuropeptide FF (NPFF), appears to be N-terminally ex-
tended by 3 amino acids (SQA) in the predicted 11 amino-
acid human neuropeptide SF (NPSF). It is likely that this 
peptide is cleaved from the precursor at Arg-65 and Arg-78; 
Gly-77 is then available for amidation. As expected for neuro-
peptide precursors, the predicted precursor contains a hydro-
phobic leader sequence of 11 amino acids at the N-terminal 
end, with its predicted cleavage site after Cys-20. 
3.2. Genomic organization of the human FMRFamide-related 
peptide gene 
PCR amplification of the gene from human genomic DNA 
was performed using primer pairs designed to the 5' and 3' 
untranslated regions (5'UTR and 3'UTR) of the cDNA clone. 
A product of »1000 nucleotides was obtained, and further 
PCR analysis with internal primer pairs (Fl/F2rev and F2/ 
F2rev) indicated the presence of 2 introns (Fig. 2). DNA 
sequencing of these genomic fragments confirmed the presence 
of 2 introns, containing classical 5' and 3' splice consensus 
sequences, at positions 267 bp (II, 227 bp in length) and 387 
bp (12, 127 bp in length) and branch site sequences. The 2nd 
intron lies within the sequence encoding the smaller peptide 
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Fig. 3. Comparison of the effects of (a) bovine NPAF vs. human 
NPAF and (b) bovine NPFF vs. human NPSF. The amplitude of 
the monosynaptic component of the reflex response evoked in lum-
bar ventral roots in isolated rat spinal cord preparations was deter-
mined in response to dorsal root stimulation. Either three or four 
dorsal roots were mounted on silver wire stimulating electrodes and 
recordings were made from ventral roots using a suction electrode. 
bridization probes. The sequence of one such clone was de-
termined (Fig. 1). This was found to contain an open reading 
frame encoding a 113-residue polypeptide (164-502 bp) con-
Fig. 4. The effects of human NPAF upon the frequency of sponta-
neous dorsal root action potentials recorded from an isolated rat 
spinal cord preparation. Each bar represents the number of action 
potentials made in 30 successive 15-s time epochs under control 
conditions (mean 8.4 ±0.7 S.E.M.) and with 10~6 M (mean 
20.4±1.4 S.E.M.) and 10"5 M (mean 32.4± 1.5 S.E.M.) human 
NPAF dissolved in oxygenated ACSF. 
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NPSF, the other between the hydrophobic leader and the 1st 
peptide. Both introns contain translational stop codons in all 
3 reading frames, eliminating the possibility of alternative 
splicing producing different peptides. 
3.3. Comparison of the effects of the human and bovine peptides 
on rat spinal cord activity 
Rat NPFF modulates opioid functions via specific receptors 
localized in the spinal cord and the brain [4,6,9,16]. This bio-
logical system was used to test the physiological effects of the 
2 novel human peptides. Changes in the amplitude of the 
monosynaptic component of the reflex response (MSR) 
evoked in lumbar ventral roots, by dorsal root stimulation 
in response to perfusion with the peptides were recorded 
(Fig. 3). Rat spinal cord preparations were perfused with bo-
vine and human RFamide peptides at concentrations between 
10 nM and 10 uM. The amplitude of the MSR was shown to 
increase significantly on application of bovine and human 
NPAF at concentrations of > 10 nM, in a dose-dependent 
manner (Fig. 3b). The effect on the MSR by the human pep-
tide was indistinguishable from that of the bovine peptide. 
Bovine NPFF also caused a significant increase in the ampli-
tude of the MSR in a dose-dependent manner although this 
effect was generally weaker than that of the bovine and hu-
man NPAF peptides. However, human NPSF showed no ef-
fect on the amplitude of the MSR at any of the concentrations 
tested (Fig. 3a). 
3.4. Effect of human NPAF on spontaneous activity in lumbar 
dorsal roots 
Spontaneous action potentials are detectable within the 
lumbar dorsal roots of isolated rat spinal cords. In order to 
determine whether human NPAF effects the level of this spon-
taneous activity, the frequency of the action potentials during 
perfusion with human NPAF, were recorded. A dose-depend-
ent increase in the frequency at concentrations of 1 |J,M 
(20.4±1.4 S.E.M.) and 10 uM (32.4±1.5 S.E.M.) from the 
basal level of activity (8.4 ±0.7 S.E.M.) was observed (Fig. 4). 
4. Discussion 
The cloning of the human FMRFamide-related peptide 
gene has revealed the structures of 2 novel neuropeptides. 
Their structures differ from those already known from bovines 
[4] by the substitutions of 2 amino acids in the longer peptide, 
NPAF, and the N-terminal extension by 3 residues of the 
shorter peptide, NPFF (human NPSF). Two introns within 
the gene were identified by PCR from genomic DNA using 
primer sites present within the cDNA sequence. Neither in-
tron contained open reading frames or splice sites other than 
those used to produce the transcript identified from the iso-
lated cDNA clone. This eliminated the possibility of alterna-
tive transcripts being produced that may encode peptides of 
different sequences, as is the case in some molluscan FMRF-
amide genes [17], as failure to remove either of the introns 
would produce truncated prepropeptides. 
The sequence similarity of human NPAF and NPSF to 
those isolated from bovines and rats, suggested that the novel 
human peptides may have similar functions in modulation of 
nociception in the spinal cord. To test this, their effects on the 
dorsal root-ventral root reflex response (DR-VRR) were com-
pared to bovine NPAF and NPFF. As can be seen in Fig. 3a, 
the monosynaptic component of the ventral root reflex re-
sponse evoked by dorsal root stimulation increased in ampli-
tude with the application of human NPAF. This increase 
paralleled that observed with the bovine peptide demonstrat-
ing that the physiological consequences of the change in the 
2 amino acids that differentiate the human from bovine pep-
tide are not significant. Human NPAF peptide also produced 
a dose-dependent increase in spontaneous extracellular action 
potentials in lumbar dorsal roots at concentrations of 1 and 
10 u.M. The importance of these observations is that the 
2 NPAF peptides appear to increase neuronal activity in re-
gions known to be involved in nociception. The change in the 
DR-VRR indicates that reflex activity in the spinal cord is 
enhanced, and the spontaneous dorsal root activity is known 
to originate in the superficial layers of the dorsal horn [18], an 
area associated with the processing of nociceptive signals. This 
supports previous data indicating that i.v. injection of 
FMRFamide-related peptides modulates morphine-induced 
analgesia [4]. In contrast, the shorter human peptide NPSF 
has no effect on the amplitude of the monosynaptic compo-
nent of the ventral root reflex response (Fig. 3b) although a 
clear increase in amplitude is seen with the addition of the 
bovine NPFF. The sequence of human NPSF is identical to 
bovine NPFF, except for the N-terminal extension of 3 amino 
acids. These data suggest that either the human peptide is 
inactive and requires proteolytic cleavage to activate it, or 
the rat NPFF receptor does not respond to the human pep-
tide. Convincing HPLC and RIA data suggests that a peptide 
with the 3 N-terminal acids deleted exists at low concentra-
tions in human serum [5]. The arginine at position 65 (Fig. 1) 
is most likely a cleavage site for a neuropeptide precursor-
processing enzyme, and the removal of the 3 most N-terminal 
amino acids to produce the functional 8-residue peptide 
NPFF may occur by the action of an aminopeptidase. Such 
N-terminal trimming by a tripeptidyl aminopeptidase is ob-
served in the metabolism of CCK-8 [19] and by the endopep-
tidase neprilysin in the nematode peptide AF1 in Ascaris suum 
[20]. In the latter example, it is striking that cleavage of this 
FMRFamide-related peptide specifically precedes a phenyl-
alanine residue as would also be the case during maturation 
of human NPSF to NPFF. Alternatively, a propeptide-proc-
essing enzyme family, the dipeptidylaminopeptidases (DPAP), 
exist in many species (reviewed in [21]). These enzymes specif-
ically cleave amino-acid pairs with the structure X-Ala or X-
Pro from the N-termini of propeptides. Such an amino-acid 
pair exists at positions 2 and 3 of the predicted human NPSF 
peptide, and thus could be removed from the 11-mer peptide 
to form the biologically active 8-mer NPFF. This processing 
event, however, would require the previous removal of Ser at 
position 1 to allow the action of a DPAP enzyme. Such N-
terminal 'clipping' of neuropeptides has been described else-
where [22] and, in conjunction with DPAP activity, could be 
responsible for this processing. 
The biological effects of vertebrate RFamide peptides in-
clude the regulation of heart rate and blood pressure [7] and 
the modulation of morphine-induced antinociception [4,6]. 
The association of these neuropeptides with the vertebrate 
male reproductive system has not previously been reported 
although FMRFamide is known to function in the molluscan 
reproductive organs [23]. It has been speculated that NPFF 
detected in human serum is the result of neural 'leakage' [24], 
however, the production of FMRFamide-like peptides by the 
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testis and their subsequent release into the circulatory system 
seems a more plausible explanation. 
The first FMRFamide-like peptides to be discovered were 
in molluscs where they were identified by their biological ac-
tivity on the isolated clam heart [1]. It is interesting to note 
that the molluscan FMRFamide peptides show a similar effect 
on molluscan heart rate as they do on the vertebrate heart, 
and that the vertebrate FMRFamide-like peptides also in-
crease heart rate. Such conservation of biological activity sug-
gests that the control of heart rate in both vertebrates and 
invertebrates is a process in which FMRFamide peptides play 
an important role. 
The isolation of the human gene encoding 2 FMRFamide-
like neuropeptides, described here, will greatly help advance 
the study of this important group of vertebrate peptides. We 
have shown the predicted peptide structures to be very similar 
to previously isolated peptides from bovines and rat. One of 
the peptides, NPAF, has indistinguishable activity on rat spi-
nal cord as its bovine homologue while NPSF appears to be 
wholly inactive. These findings will allow the extrapolation of 
results using rat and bovine peptides in physiological studies 
to their probable effects in humans. 
Note added in proof: The cDNA sequence is available on 
GenBank, accession no. AF005271. 
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